Pharmacokinetics of Ceftaroline in the Central Nervous System Are Favorable for Meningitis Therapy

Enhanced penetration of ceftaroline into inflamed meninges would allow sufficient pharmacokinetic exposure against pathogens with MIC ≤1 mg/L.

The cephalosporin ceftaroline restores beta-lactam activity against methicillin-resistant Staphylococcus aureus (MRSA) and is approved for skin and soft-tissue infections and community-acquired pneumonia. Ceftaroline also appears favorable for treating meningitis, but adequate pharmacokinetic studies of its penetration into the central nervous system have been limited.

Helfer and colleagues developed a population pharmacokinetic model of ceftaroline distribution in soft tissue and cerebrospinal fluid (CSF) to assess the probability of target attainment across the recommended dosing interval. Plasma and microdialysate samples of subcutaneous tissue and muscle were obtained from 12 healthy volunteers following infusion of 600 mg ceftaroline (t…

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases